# Appendix C – Key dates for the Post-market Review of Ezetimibe

| **Date** | **Milestone** | **Notes** |
| --- | --- | --- |
| 14 August 2015 | PBAC recommended Post-market Review | Purpose of the Review was to consider cost-effectiveness |
| 28 September 2015 | Ministerial approval to commence Review | NA |
| 16 October – 13 November 2015 | Public consultation on draft TOR (4 weeks) | Consultation period was initially due to end 30 October 2015 but was extended. Five submissions were received.  |
| 11 December 2015 | PBAC considered final TOR | NA |
| 24 February 2016 | Ministerial approval of final TOR | NA |
| 4 March 2016 – 22 April 2016 | Public consultation on final TOR (7 weeks)  | Six submissions received. |
| 10 May 2016 | Engaged evaluator group | Official order between the Department of Health and Deakin University signed  |
| 30 June 2016 | Reference Group meeting 1 | Ten Reference Group members attended. Discussed: * TOR
* Consumer and stakeholder input
* Evidence evaluation – Research questions for Literature Review; Utilisation Review
 |
| 23 September 2016 | Draft report from evaluator group | NA |
| 23 September 2016 | Reference Group meeting 2 | Twelve Reference Group members attended. Discussed: * Review progress
* Evidence evaluation - Final research protocol; draft Literature Review report; draft Utilisation Review report
* External reports
* Stakeholder forum
 |
| 11 November 2016 | Stakeholder forum | Outcome statement at **Appendix F** |
| 23 November 2016 | Final report from evaluator group | NA |
| 30 November 2016 | Reference Group meeting 3 | 12 Reference Group members attended.Discussed* Draft Review Report
 |
| 22 December 2016 | Draft Review Report to ezetimibe sponsor  | NA |
| 25 January 2017 | Pre subcommittee response received from sponsor (draft Review Report) | NA |
| 30 January-10 February 2017 | Public consultation on draft Review Report (2 weeks) | 14 submissions received |
| 2-7 February 2017 | ESC/DUSC consideration of draft Review Report | Further analysis requested |
| 14 March 2017 | ESC/DUSC advice provided to sponsor | NA |
| 17 March 2017 | Reference Group Meeting 4 (to finalise the draft Review Report) | Ten Reference Group members attended.Discussed:* Stakeholder submissions
* Finalise Review Report
 |
| 29 March 2017 | Sponsor pre PBAC response received (draft Review Report)[[1]](#footnote-1) | NA |
| 10 May 2017 | *Revised* draft Review Report to sponsor | NA |
| 23 May-6 June 2017 | Public consultation on *revised* draft Review Report | 7 submissions received |
| 24 May 2017 | Pre subcommittee response received from sponsor (*revised* draft Review Report) | NA |
| 1-6 June 2017 | ESC/DUSC consideration of *revised* draft Review Report | NA |
| 21 June 2017 | ESC/DUSC advice provided to sponsor | NA |
| 28 June2017 | Sponsor pre PBAC response due | NA |
| 5-7 July 2017 | PBAC consideration of Review Report and advice to Government | NA |
| Mid-late 2017 | Ministerial consideration of Review Report | NA |

Abbreviations: ESC, Economics Sub Committee; DUSC, Drug Utilisation Sub Committee; NA, Not applicable; TOR, Terms of Reference.

1. The *original* draft Review Report was not considered by the PBAC in March 2017. [↑](#footnote-ref-1)